Holen Sie sich die Stockscreener-App
17.56
7.29%
-1.38
Vorhandelsmarkt:
18.01
0.45
+2.56%
Spyglass Pharma Inc Aktie (SGP) Neueste Nachrichten
SpyGlass Taps Shannon Treviño as General Counsel - Orange County Business Journal
SpyGlass Pharma appoints Shannon Treviño as general counsel to support Phase 3 trials and commercialization plans. - Pluang
SpyGlass Pharma, Inc. Announces Appointment of Shannon Treviño to General Counsel - marketscreener.com
SpyGlass Pharma appoints Shannon Treviño as general counsel - Investing.com
SpyGlass Pharma appoints Shannon Treviño as general counsel By Investing.com - Investing.com Canada
SpyGlass Pharma Appoints Shannon Treviño as General Counsel - GlobeNewswire
Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP - MarketBeat
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing - VisionMonday.com
SpyGlass Pharma appoints Mike Pinder as VP of marketing By Investing.com - Investing.com South Africa
SpyGlass Pharma appoints Mike Pinder as VP of marketing - Investing.com
Drop-free glaucoma BIM-IOL system taps veteran marketer - Stock Titan
SGP Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesProfit Announcement - newsline.com
SpyGlass Pharma to Participate in Upcoming Investor Conferences - Sahm
SpyGlass Pharma: New add-on CPT code supports BIM-IOL System - Eyes On Eyecare
SpyGlass Secures Billing Code for IOL Platform - Orange County Business Journal
Spyglass Pharma IncBIM-Iol System Phase 3 Trial Enrollment Expected To Complete In 2027 - TradingView
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System - GlobeNewswire
SpyGlass Pharma (SGP) Q1 2026 Earnings Miss by Significant: Key TakeawaysBuyback Authorization - newser.com
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance By Investing.com - Investing.com South Africa
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance - Investing.com India
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Sahm
Number of shareholders of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
SpyGlass Pharma (SGP) boosts cash to $251M after IPO while losses widen - Stock Titan
SpyGlass Pharma (SGP) boosts cash with IPO and reports strong BIM-IOL glaucoma data - Stock Titan
SpyGlass Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spyglass Pharma (SGP) Institutional Ownership 2026 $SGP - MarketBeat
Eye implant ended IOP-lowering drops for 98% in trial - Stock Titan
SGP SpyGlass Pharma reports solid late-stage trial progress, lays out aggressive commercial expansion plans for 2025.Stock Community Signals - newser.com
What fair value gap SpyGlass Pharma (SGP)? (Buying Pressure) 2026-05-01Inside Day Breakout - newsline.com
SGP Ownership | SPYGLASS PHARMA INC (NASDAQ:SGP) - ChartMill
Eye care firm SpyGlass Pharma soars 65% in trading debut - MSN
SGP Technical Analysis | Trend, Signals & Chart Patterns | SPYGLASS PHARMA INC (NASDAQ:SGP) - ChartMill
All News for SGP : SpyGlass Pharma, Inc. - Zacks Investment Research
Dividend HistorySpyGlass Pharma, Inc. (SGP) - Zacks Investment Research
Is SpyGlass Pharma (SGP) Stock Good for Long Term | Price at $22.30, Down 0.71%Earnings Miss Risk - newsline.com
SpyGlass Pharma, Inc.: Fundamental Analysis and Financial Ratings | SGP | US85220G1094 - marketscreener.com
SGP: SpyGlass Pharma, Inc.Insider Transations - Zacks Investment Research
SpyGlass Pharma, Inc. (SGP) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
SpyGlass Pharma Reports Fourth Quarter and Full-Year 2025 Results - VisionMonday.com
SpyGlass Pharma, Inc. (SGP) stock price, news, quote and history - Yahoo Finance UK
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):